Example of active therapeutic drug-monitoring: Itraconazole;Exemple de suivi thérapeutique actif : L'itraconazole

Therapie

Volumn 51, Issue 5, 1996, Pages 502-506

  Levron, J C ^a   Moing, Le ^a   Chwetzoff, E ^b  

^a Janssen Research Foundation   (France)

^b Laboratoires Jannsen Cilag   (France)

Author keywords

Anti fungal; Drug monitoring; Itraconazole; Pharmacokinetic

Indexed keywords

DRUG METABOLITE; HYDROXYITRACONAZOLE; ITRACONAZOLE; ANTIFUNGAL AGENT;

CONFERENCE PAPER; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG MONITORING; DRUG SAFETY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MORTALITY; MYCOSIS; PHARMACOKINETICS; PRIORITY JOURNAL; STEADY STATE; ARTICLE; BLOOD; DRUG COMBINATION; FOLLOW UP; IMMUNE DEFICIENCY;

ANTIFUNGAL AGENTS; DRUG MONITORING; DRUG THERAPY, COMBINATION; FOLLOW-UP STUDIES; HUMANS; IMMUNOCOMPROMISED HOST; ITRACONAZOLE;

EID: 0030224281     PISSN: 00405957     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Yéni P. Perspectives médicamenteuses dans le traitement de l'aspergillose invasive. Pathol Biol 1994; 42: 700-705.
2. Barone J, Koh J, Bierman R et al. Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers. Antimicrob Agents Chemother 1993; 37: 778-784
3. Lim SG, Sawyer AM, Hudson M, Sercombe J et al. Short report : the absorption of fluconazole and itraconazole under conditions of low intragastric acidity. Aliment Pharmacol Ther 1993; 7: 317-321
4. Heykants J, Van Peer A, Van de Velde V, Van Rooy P, Meuldermans W, Lavrijsen K et al. The clinical pharmacokinetics of itraconazole : an overview. Mycoses 1989; 32: 67-87.
5. Tucker R, Denning D, Hanson L, Rinaldi M, Graybill J, Sharkey K. et al. Interaction of azoles with rifampicine and carbamazepine in vitro and clinical observations. CID 1992; 14: 165-174.
6. Heykants J, Michiels M, Meuldermans W et al. The pharmacokinetics of itraconazole. In: Fromtling RA, ed. Animals and man : an overview. Recent trends in the discovery, development and evaluation of antifungal agents. South Africa: JR Prous Sciences Publishers, 1987.
7. Woestenborghs R, Lorreyne W, Heykants J. Determination of itraconazole in plasma and animal tissues by high-performance liquid chromatography. J Chromatogr 1987; 413 : 332-337.
8. Law D, Moore C, Denning D. Bioassay for serum itraconazole concentrations using hydroxyitraconazole standards. Antimicrob Agents Chemother 1994; 38: 1561-1566.
9. Hosteller J, Heykants J, Clemons K et al. Discrepancies in bioassay and chromatography determinations explained by metabolism of itraconazole to hydroxyitraconazole : studies of interpatient variations in concentrations. Antimicrob Agents Chemother 1993; 37: 2224-2227
10. Van't Wout JW, Novakova I, Verhagen CAH et al. The efficacy of itraconazole against systemic fungal infections in neutropenic patients : a randomised comparative study with amphotericin B. J Infection 1991; 22: 45-52
11. Boogaerts MA, Verhoef GE, Zachee P. et al. Antifungal prophylaxis with itraconazole in prolonged neutropenia : correlation with plasma levels. Mycoses 1989; 32: 103-108.
12. Van Custen J. The in vitro antifungal spectrum of itraconazole. Mycoses 1989; 32: 7-13.